Podcasts about Metastatic breast cancer

In metastatic breast cancer, resistance to therapy remains one of the most challenging aspects to care. A key driver of resistance in hormone receptor-positive, HER2-negative disease is the ESR1 mutation, a genetic change that alters the estrogen receptor and limits the effectiveness of certain standard therapies. In this episode, CANCER BUZZ speaks with Eleonara Teplinsky, MD, FASCO, head of breast and gynecologic medical oncology at Valley-Mount Sinai Comprehensive Cancer Care, about how the ESR1 mutation shapes treatment decisions and explains communication strategies, such as the "lock-and-key" model. Then CANCER BUZZ speaks with Maimah Karmo, president and CEO of Tigerlily Foundation about the importance of communicating with patients in ways that foster clarity and compassion through relatable analogies. Guest: Eleonora Teplinsky, MD, FASCO Medical Oncologist Valley Mount Sinai Comprehensive Cancer Care Paramus, NJ Maimah Karmo President/CEO Tigerlily Foundation "If you had molecular testing of your tumor done at the time of diagnosis, that may not be enough. If there is disease progression, we might need to repeat it. So it's really important to stress that there are points in the disease course where we're going to be checking for these biomarkers." - Teplinsky "The more that we can know about the tumor, how it's going to behave, what treatment it may or may not respond to, really can help us." - Teplinsky "Having a physician that is a true partner with the patient, that has a relationship, that's trusted, and that feels safe and secure, it's really, really critical." - Karmo Resources: Unlocking the Conversation: Navigating ESR1 Mutations in Metastatic Breast Cancer

Drs. Lynce and Waks explore whether advances in HER2-targeted therapy are making metastatic HER2+ breast cancer potentially curable, highlighting long-term remissions, survival gains from trials, and ongoing studies testing treatment-free remission.

Finding balance isn't about perfection — it's about learning what works for you. In this episode, Heather and Larry dig into the daily juggling act of work, health, and real life while managing metastatic breast cancer. They talk about scheduling versus spontaneity, energy management, and how both structure and grace play a role in living well long-term.Heather Jose was diagnosed with stage IV breast cancer at age 26 and has been thriving for more than 25 years. Through her podcast I'm Still Here: Lessons from Life with Metastatic Breast Cancer, she shares honest conversations, hope, and practical ways to live fully — no matter what life looks like.

Show notes and links: www.chrisbeatcancer.com/how-karla-mans-giroux-healed-metastatic-breast-cancer

Featuring perspectives from Dr Aditya Bardia and Dr Adam M Brufsky, including the following topics: Introduction: Antibody-drug conjugates in localized breast cancer (0:00) Case: A frail woman in her late 70s with ER-positive, HER2-low metastatic breast cancer (mBC) receives sacituzumab govitecan after multiple lines of therapy — Eric Fox, DO (7:46) Case: A woman in her early 60s with NTRK-mutant ER-negative, HER2-low recurrent mBC receives trastuzumab deruxtecan — Lai (Amber) Xu, MD, PhD (21:07) Case: A woman in her mid 70s with PIK3CA-mutant recurrent metastatic triple-negative breast cancer who developed a diverticular abscess on neoadjuvant chemoimmunotherapy receives sacituzumab govitecan and pembrolizumab — Alan B Astrow, MD (31:49) Case: A woman in her mid 60s with ER-negative, HER2-low mBC receives sacituzumab govitecan after experiencing disease progression on capecitabine — Laila Agrawal, MD (38:37) Case: A woman in her late 50s with ER-negative, HER2-low mBC receives trastuzumab deruxtecan after experiencing disease progression on sacituzumab govitecan — Kimberly Ku, MD (44:24) Case: A woman in her early 60s with ER-positive, HER2-low mBC and hyperglycemia receives trastuzumab deruxtecan after experiencing disease progression on capivasertib/fulvestrant — Eleonora Teplinsky, MD (48:50) CME information and select publications

Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.CME information and select publications here.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to feature a comprehensive review of the current management of metastatic breast cancer, emphasizing evidence-based treatment strategies across molecular subtypes, toxicity management, and patient-centered care. Drs Armstrong and Tawagi discussed that the primary goals of metastatic breast cancer therapy include prolonging survival, controlling symptoms, minimizing toxicity, improving quality of life, and incorporating patients' goals and preferences into care decisions. Their discussion also highlighted the importance of recognizing when transitioning to best supportive care is most appropriate. For estrogen receptor–positive metastatic breast cancer, they noted that first-line therapy includes an aromatase inhibitor or fulvestrant (Faslodex) combined with a CDK4/6 inhibitor, with ovarian function suppression for premenopausal patients. PARP inhibitors are recommended for patients with BRCA1/2-positive disease. In visceral crisis, chemotherapy remains the category 1 recommendation. Second-line treatment options include therapies guided by repeat molecular testing. fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) is approved for patients with HER2-low disease. For HER2-positive metastatic breast cancer, first-line treatment consists of a taxane plus pertuzumab (Perjeta) and trastuzumab (Herceptin), followed by T-DXd in the second-line setting. For triple-negative metastatic breast cancer, therapy depends on PD-L1 status. The episode concluded by underscoring the role of bone-protective agents such as zoledronic acid, pamidronate, or denosumab (with dental clearance to prevent osteonecrosis). Key takeaways emphasize tailoring therapy to molecular subtype, recognizing drug-specific toxicities, and prioritizing patient-centered decision-making in the management of metastatic breast cancer.

This week's episode is part 3 of our breast cancer series, with a 2025 update focusing on metastatic breast cancer systemic therapies, toxicities, and supportive care considerations. 

In this episode of, "Empowered Intimacy: Getting Your Sexy Back After Breast Cancer," we open up an important conversation about sexual health after a breast cancer diagnosis. Melissa is joined by her friend Deltra, a mom of five living with triple-negative metastatic breast cancer, and Dr. Laila Agrawal, a board-certified medical oncologist dedicated to putting sexual health at the forefront of cancer care. Many carry these concerns silently, but intimacy is an important part of quality-of-life care. Together, they share personal stories, explore why this topic is often overlooked, and offer practical tips for starting the conversation with your doctor, asking the right questions, and advocating for the support and resources that you deserve. Special thanks to Lilly, Merck, and Novartis for supporting the Cancer Fashionista Foundation and making this episode possible.

Let's Talk About Sex – After CancerAfter cancer, everyone tells you “you look great”—but looking fine isn't the same as feeling whole. In this candid, funny, and deeply honest conversation, Heather and Larry talk about what intimacy really looks like after diagnosis and treatment: grief over a changing body (and lost fertility), reconstruction that “looks” like breasts but doesn't feel like them, early menopause, fear, shame, and how they slowly rebuilt connection.They share the practical stuff that helped—clear boundaries, encouragement and praise from a partner, scheduling intimacy, using vibrators to reduce dryness and re-awaken sensation, and giving each other permission to learn by trial and error. If you've ever wondered how to move from surviving to fully living—including in the bedroom—this one's for you.We cover:Appearance vs. reality: looking “okay” while feeling disconnectedReconstruction + sensation loss, and naming what doesn't workGrieving fertility and redefining womanhoodPartner role: encouragement, praise, patience, teamworkPractical tools: communication, timing, scheduling, lube, vibratorsKeeping humor alive when things get awkwardContent note: frank discussion of sex, bodies, vibrators, and intimacy after cancer.✨ Connect with Heather:Website: heatherjose.comInstagram: @heatherjoseFacebook: Heather Jose – I'm Still HereYouTube: I'm Still Here PodcastPodcast: I'm Still Here: Lessons from Life with Metastatic Breast Cancer

Featuring an interview with Dr Laura Huppert, including the following topics: General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00) Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44) Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30) Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13) Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25) CNS penetration and activity of ADCs in the treatment of breast cancer (22:27) Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24) Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05) Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51) Ongoing evaluation of ADCs in the localized disease setting (35:42) Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38) CME information and select publications

Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer. CME information and select publications here.

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare professional questions on how to personalize therapy for these patients. Supported by an educational grant from Lilly.Faculty:Manali Bhave, MDMedical Director, Phase I Clinical Trials UnitAssistant ProfessorDepartment of Hematology and OncologyWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaErin F. Cobain, MDAssociate Professor of Internal MedicineDivision of Hematology/OncologyBreast Oncology ProgramUniversity of Michigan Rogel Cancer CenterAnn Arbor, Michigan Link to obtain CME/CE credit:https://bit.ly/4nUJO1OLink to Oncology Breast Cancers with additional educational activities:https://bit.ly/4nNGlBY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

During National Breast Cancer Awareness Month, breast cancer gets more attention and that is a great thing for fundraising, awareness and early detection. However, for those living with Metastatic Breast Cancer, this month can be hard – and sometimes feel triggering and isolating. The widespread focus is often on screenings and celebrating survivors living a life free from cancer, which is not the reality for those with metastatic disease. Today, on MBC Awareness Day, we are excited to welcome Ashley Fernendez back to the show to talk about her lived experiences, how she seeks support and what she wants people to know about living with Metastatic Breast Cancer.

In this raw, funny, and beautifully honest episode, Wren, the founder of the Living Our Breast Lives Podcast, is joined by the vibrant Annie Bond—a woman who's not just living with Metastatic Breast Cancer, but marking an incredible 10 years of thriving with it. Annie invites us beyond the diagnosis and into her world: her advocacy, her comedy, her social media voice, and her unapologetic authenticity.We dive into the realities of MBC—from the milestone of a decade with the disease to the heartbreak of a recent breakup and painful losses we experience so often in this community. Annie shares how she uses dark humor and creativity to cope, how advocacy keeps her grounded, and why building authentic connections—online and in person—has been one of the greatest gifts of this journey.She also opens up about the balance between laughter and grief, joy and sorrow, and why honesty matters more than toxic positivity ever could. Through it all, Annie reminds us that even in the hardest spaces, community and truth-telling can carry us forward.Whether you're living with MBC, love someone who is, or just want to hear a bold and unfiltered story of resilience, humor, and heart—this episode is for you. It's real, it's raw, and it's proof that even in the face of stage four, life can still be loud, messy, meaningful—and full of laughter.Living Our Breast Lives Information:Email: livingourbreastlivespodcast1@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morrAnnie Bond's Information:@theanniebond on FB, IG, and TikTok

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics: Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00) Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18) Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10) CME information and select publications

Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

This episode is all about the purisuit to understand and treat metastatic breast cancer. Dr. Martine Piccart and Dr. Lisa Carey delve into the complexities of metastatic breast cancer (MBC), highlighting why it remains one of the most challenging forms of the disease to treat.

October is a complicated month for so many of us touched by breast cancer. Pink ribbons are everywhere—sometimes they feel celebratory, other times they stir up fear, grief, or difficult memories. Both experiences are real, and both deserve to be honored. In this episode, I invite you to see October through a different lens. Instead of focusing only on awareness, what if we made it about aliveness? I talk about how prevention deserves as much energy as detection, why metastatic breast cancer looks very different today than it did 10–15 years ago, and how daily acts of self-love—like steadying blood sugar, protecting sleep, or moving your body—can transform both health and quality of life. This conversation is about shifting from fear to empowerment, from bracing for bad news to showing up fully for the life that's happening right now. Think of it like a rhinestone ribbon—multi-faceted, sparkly, unapologetically alive.

Living with metastatic breast cancer is exhausting—physically, mentally, emotionally, and socially. It never takes a day off, and sometimes you just wish you could too. In this episode of I'm Still Here: Lessons from Life with Metastatic Breast Cancer, Heather explores the very real longing to take a “vacation” from MBC.You'll hear why the constant weight of appointments, scanxiety, side effects, and even other people's expectations can feel overwhelming—and why it's perfectly normal to want a break. More importantly, you'll discover small but powerful ways to give yourself permission to rest, escape, and find peace, even if cancer never fully leaves the room.

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice. CME information and select publications here.

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics:  Introduction: ER-Positive Metastatic Breast Cancer — Bringing Research Data into Practice (0:00) Key Issues from the General Medical Oncologists (GMO) Survey (3:43) Faculty Cases and GMO Questions (44:43) CME information and select publications

“She's triple negative and has a very, very aggressive tumor. Instead of going on spring break that year, she sat in our chemo room and got chemo. Her friends from college are good to try to keep her involved and try to surround her and encourage her, but they're right now in very, very different spots in their lives. She's fighting for her life; her friends are fighting for the grade they get in a class—and that's different,” ONS member Kristi Orbaugh, MSN, NP, AOCN®, AOCNP®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about metastatic breast cancer in adolescent and young adult patients. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 354: Breast Cancer Survivorship Considerations for Nurses Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities Episode 307: AYAs With Cancer: Financial Toxicity Episode 300: AYAs With Cancer: End-of-Life Care Planning ONS Voice articles: ‘Cancer Ghosting' May Add Another Layer of Emotional Burden for Patients Discoveries in Race-Related Breast Cancer Biomarkers May Improve Precision Treatments What Is HER-2-Low Breast Cancer? What Oncology Nurses Need to Know About Supporting AYAs With Cancer ONS books: Guide to Breast Cancer for Oncology Nurses Oncology Nursing Forum articles: An Integrative Review of the Role of Nurses in Fertility Preservation for Adolescents and Young Adults With Cancer Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers ONS huddle cards: Altered Body Image Fertility Preservation Sexuality Other ONS resources: Breast Cancer Learning Library Fertility Preservation in Individuals With Cancer ONS Biomarker Database American Cancer Society's breast cancer resources American Society of Clinical Oncology continuing education resources Elephants and Tea Life, Interrupted Livestrong National Cancer Institute's breast cancer resources Stupid Cancer Young Survival Coalition To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we use ‘adolescent and young adult,' we're really talking about age 19–35. Some groups will say 15–39, but right around that age. When we think about that age, think about what all could be going on during those ages. Late teenagers, they may be going off to college, they may be graduating high school, trying to set up their own life, trying to become independent from mom and dad. If you're talking about early to mid 30s, you could be talking about young parents, young career folks. So, just setting that into place makes you realize this can be a very tumultuous time for folks.” TS 2:06 “Unfortunately, this group tends to have more aggressive subtypes. We see more triple-negative in this group. We see more hormone-negative, HER2-positive in this group. Normal breast cancer cells should be stimulated by hormone. They are stimulated by hormones. So when you have a breast cancer cell that is not driven by hormones, it's much more difficult to treat. We tend to see more aggressiveness in these tumors. We also see a higher incidence in non-Caucasian folks in this age group compared to the older age groups.” TS 4:53 “I think we have gotten much better about understanding the importance of fertility preservation and getting reproductive endocrinologists in, sooner rather than later. If we have earlier-stage cancers and we have patients that want to try to preserve eggs, preserve fertility, sperm banking. … If you have that time to talk to them—maybe a 21-year-old—the primary thing on her mind is not how many children she wants to have one day. Maybe she's not even thought about having kids yet. It's still a question you need to [ask]. Do you want to try to preserve fertility? Do you want to try to harvest some eggs? That's a conversation that needs to be had and is very, very important for that age group.” TS 10:35 “One thing that helps is if you can get them [into] reputable support groups with people their own age that are going through what they're going through. Someone else that doesn't have hair, someone else that isn't going to make it to the big board meeting or isn't going to get the promotion this year because they've had to take a medical leave. Someone else that understands it differently.” TS 16:47 “In breast cancer, many of those biomarkers just get reflexed. And what I mean by reflexed is a breast cancer pathology comes through, or a breast cancer specimen comes through, and it just automatically gets tested for X, Y, Z. HER2 and of course ER/PR. Now we understand that we don't just need to know whether they're HER2 positive or HER2 negative. We need to know: What is the IHC score? And even if the IHC score is zero, is there any membrane staining? And then we need to know what's their ESR1, their PTEN, their AKT, their PIK3CA. Those are so important to know.” TS 18:11 “I think it's important to try to remember what our priorities were when we were in our 20s—what our priorities were when we were starting out as young mothers or starting out our career. Because that's where these folks are. … I can't imagine in the midst of college, when I'm trying to be independent, to suddenly have to be at home and rely on my mom to take me to my chemo appointment. … So I think one really important bias is to remember where they are in the developmental stages of life. They're not 40-something. They haven't lived X amount of life, and we need to take a step back and try to remember when we were their age, what was important to us? Where were our priorities at that point? And then hear them when they're telling us what's important to them.” TS 29:22 “From a female standpoint … we frequently throw these patients into menopause or have early menopausal symptoms, and I think we forget how devastating that can be. … They now are at higher risk for osteopenia or osteoporosis. … And then we tell people, ‘Be as normal as possible, get back and do those normal things.' Well, they're in a relationship, and they want to be intimate [but] suddenly having sexual intercourse is incredibly painful. Or if it's not painful, sometimes they've just lost pure interest in that. They don't feel confident about their body. All of those things need to be addressed because patients are trying to live each day as normally as possible.” TS 31:55 

Can you give patients one ADC after another? A renowned panel of experts interrogate this question and many more in this thought-provoking program. Credit available for this activity expires: 8/25/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002851?ecd=bdc_podcast_libsyn_mscpedu

Join here for expert analysis of the latest clinical trial data in HR-positive MBC and discussion of the clinical implications of these study results. Credit available for this activity expires: 8/18/2026  Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002835?ecd=bdc_podcast_libsyn_mscpedu

Anticipating and managing CDK4/6 inhibitor toxicities in HR+ HER2- breast cancer is essential to improving patient quality of life and optimizing clinical outcomes. In this episode, CANCER BUZZ speaks with Diana Van Ostran, PharmD, BCOP, clinical pharmacy specialist – breast clinic at Miami Cancer Institute, Baptist Health South Florida, about strategies to monitor and manage treatment-related adverse events in patients with early-stage and metastatic breast cancer receiving CDK4/6 inhibitors. She discusses the importance of individualized care and robust patient education around lifestyle and dietary techniques to improve tolerance of this treatment.   Diana Van Ostran, PharmD, BCOP  Clinical Pharmacy Specialist – Breast Clinic Miami Cancer Institute Baptist Health South Florida  Miami, FL   “Clinical pharmacists play a vital role in managing the patient's treatment. Because, as we know, if you're having excessive side effects, patients are going to be less likely to take their medications.”   Resources: ACCC Adverse Event Management for CDK Inhibitors in HR+ Breast Cancer ACCC CDK Inhibitors Management Miami Cancer Institute ACCC Spotlight on Miami Cancer Institute: The Role of a Breast Cancer Clinical Pharmacy Specialist for CDK4/6 Inhibitor Management

Featuring an interview with Dr Hope S Rugo, including the following topics: Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00) Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03) Management of common toxicities with approved ADCs (10:48) Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17) Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for HER2-positive metastatic breast cancer (21:09) CME information and select publications

Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational antibody-drug conjugates for endocrine-resistant HR-positive and triple-negative metastatic breast cancer. CME information and select publications here.

CME credits: 0.25 Valid until: 29-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/adcs-across-the-spectrum-of-her2-expression-in-metastatic-breast-cancer/32202/ In this Virtual Case Clinic, explore three patient case examples with Dr. Mahtani as she demonstrates the application of the latest clinical evidence in HER2-positive, HER2-low, and HER2-ultralow metastatic breast cancer. By illustrating the use of antibody-drug conjugates in HER2-expressing disease, participants will gain insights into optimal evidence-based treatment selection based upon HER2 expression. =

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics: Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00) Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49) Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44) Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29) Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19) CME information and select publications

This podcast is the audio from a special Virtual Support Group meetup featuring guest moderator Joanna Doran. Listen to the podcast to hear Joanna and Community members discuss: Medicaid changes that may happen, including the work requirement the long-term disability approval process having both Medicaid and Medicare

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancerInteractive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancerOutcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs Program faculty:Laura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Shipra Gandhi, MD, MSAssociate ProfessorDirector, Breast Translational ResearchGlenn Family Breast CenterWinship Cancer Institute of Emory UniversityAtlanta, GeorgiaResources:To access the interactive patient cases associated with this podcast discussion, please visit the program page, to access a recording from a live webinar, and an interactive decision support tool on this topic.

DISCLAIMER: This episode contains emotionally sensitive content around breast cancer. Listener discretion advised. 1 in 8 women will be diagnosed with breast cancer in their lifetime—but behind every statistic is a deeply personal story. In this raw and powerful episode of The Empower Hour, we're doing things a little differently. Instead of the usual intro, we're handing the mic directly to our guests: Amy Brace and Jacquelyn Vranicar, co-creators of the upcoming One in Eight documentary and founder of VraniCURE.org. This episode explores the inspiration behind a project that's more than just a film—it's a movement of healing, honoring, and amplifying the voices of previvors, survivors, and thrivers. From the heartbreak and hope in each story to the bold vision of creating a safe space for storytelling, Amy and Jackie take us behind the scenes of a taping event unlike any other. We talk about: The emotional impact of the documentary Why pampering and storytelling go hand-in-hand Common misconceptions about breast cancer and metastatic diagnoses The difference between “previvor,” “survivor,” and “thriver”—and why language matters What Amy and Jackie hope this film changes for future generations

First-Line Therapy—Has the Standard of Care Shifted for Good?In this episode, Dr. Sara Tolaney, of Dana-Farber Cancer Institute, discusses how DESTINY-Breast09 is redefining first-line treatment in HER2-positive metastatic breast cancer. She explores whether T-DXd plus pertuzumab should replace the long-standing THP regimen, the future role of induction-maintenance strategies, and open questions on optimal therapy duration.   Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

Fourteen years ago, I received a diagnosis that changed my life: breast cancer. It wasn't just a medical moment—it was a wake-up call. And today, I don't celebrate a “cancerversary.” I honor my Awakening Day—the day my life began shifting toward deeper healing, stronger purpose, and more intentional living. In this episode, I share what post-traumatic growth has looked like for me, how I've evolved over the last 14 years, and 14 life-changing lessons that have helped me build a life that's better than before breast cancer™. If you've ever felt like cancer took something from you that you can't get back… this episode is for you. Because healing is not just about your body—it's about your heart, your spirit, and your future.  

This podcast is the audio from a special Virtual Support Group featuring guest moderator Kelly Grosklags. Listen to the podcast to hear Kelly and Community members discuss: why you might not want to share tough emotions with the people in your life how to tell someone you need them to listen, not fix things how different members of the group shared their diagnosis with family and friends

Send us a text“I had to get out of survival mode—and I have to live. You can do both at the same time.” – CeeCee McGriffIn this powerful replay, I sit down with CeeCee McGriff, a two-time breast cancer survivor and the founder of Survive and Live Life, a nonprofit dedicated to helping others boldly share their stories of survival. From treatments and surgeries to navigating the emotional aftershocks of cancer, CeeCee's mission is to remind survivors that it's possible to both survive and truly live.After receiving her second diagnosis, CeeCee made the courageous decision to undergo a double mastectomy with reconstruction—and in doing so, stepped into a new chapter of advocacy, healing, and joy.In our conversation, we talked about:Her journey through the toughest moments of her lifeLearning to live fully after living in survival modeThe power of second opinions in healthcareWhat to say—and what NOT to say—to someone going through cancerIf you or someone you love is in need of encouragement or support, connect with CeeCee:  Linktree: https://linktr.ee/surviveandlive Her story is also featured in the book: Reform Pinktober: Profound Story Sharing Behind the Pink Ribbon Available now on Amazon — all proceeds go to Stage 4 Metastatic Breast Cancer research.In loving memory of Jackie Brown "Whoever you hold in your heart is forever and always a part of you."Let's connect: Website: www.arlenebolden.com | FB: @thepathpodcast | IG: @thepath_podcast | thepath4ward@gmail.com Follow, share and subscribe to The Path Podcast on Apple, Spotify, Youtube & other podcast platforms. Don't forget to rate and review if you enjoyed this episode! Your support helps us bring you more powerful conversations.

Dr Harold Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Joyce O'Shaughnessy and moderator Dr Hope S Rugo present data informing treatment decision-making for patients with metastatic breast cancer at the 2025 ASCO annual meeting. CME information and select publications here.

Featuring perspectives from Dr Harold J Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Hope S Rugo and Dr Joyce O'Shaughnessy, moderated by Dr Rugo, including the following topics: Introduction (0:00) Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Cortés (3:52) Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Kalinsky (23:10) Available Therapies for Patients with HR-Positive, HER2-Negative Disease Progressing on CDK4/6 Inhibition — Dr Burstein (48:09) Current and Potential Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr O'Shaughnessy (1:04:00) Current and Future Strategies for Patients with Endocrine-Refractory HR-Positive mBC — Dr Rugo (1:22:28) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Prof Dent (1:42:51) CME information and select publications

“That's what metastatic breast cancer looks like now—patients can live an extended period of time. And sometimes I think we forget to cheer for stable disease. I tell patients they can live with weeds in their garden; they just can't let the weeds take over their garden. And today we don't have a cure. We live in a rapidly changing time in oncology, and so there's just so much hope right now that we can offer patients,” ONS member Kristi Orbaugh, RN, MSN, RNP, AOCN®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about patient communication in the metastatic breast cancer setting. This podcast episode was developed by ONS through a sponsorship from Lilly. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: Episode 354: Breast Cancer Survivorship Considerations for Nurses Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities ONS Voice articles: Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options What Is HER2-Low Breast Cancer? ONS books: Guide to Breast Care for Oncology Nurses ONS course: Breast Cancer Bundle Oncology Nursing Forum article: Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers ONS Biomarker Database American Cancer Society breast cancer resources METAvivor National Cancer Institute resources: Breast cancer—Patient version To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “I think the most important and vital piece of having those conversations is making sure that we know—really know—that patient, because if we know them, that helps guide what they're needing right then, helps guide our verbiage, helps guide disciplines that we bring in.” TS 2:04 “What do they want to hear? I've been in practice a really, really long time, and I've had the entire spectrum. I've had patients say, ‘Tell me every single detail.' I mean, they want pictures. They want graphs. They want me to draw things. I've even had patients that want me to take markers and mark their body parts. … And then I've had patients that say, ‘I don't want to know anything. I trust my healthcare team. I'm going to proceed with treatment, but I really don't want to know anything.'” TS 3:40 “Remember to make things as simple as possible until we really know what the patient knows. We don't send our children to school and start them out in eighth grade; we send them to kindergarten for a reason. So we get basic information, and then we build on that. And I think we need to remember that when we're doing our patient education, whether it's regarding new chemotherapy or treatment plans or palliative care, we've got to remember to start simple. And maybe we build on that very quickly, or maybe it takes a bit more time. Number one—I actually think it helps with adherence because patients understand what we're asking of them and why we're asking that of them.” TS 12:00 “I think what's really kind of key to keep in mind is that patients are going to seek information. And so, we need to make sure that we're giving them really good, reliable, durable information because if we are not giving them good websites, if we're not giving them good written material, if we're not giving them good verbal information and education, they're going to contact ‘Dr. Google.' Dr. Google is good for a lot of things, but sometimes patients can go down a rabbit hole that's not appropriate or not accurate. That's not a good place for them to be.” TS 14:35 “If we find biomarkers that we call actionable, meaning that we find this mutation and we have a drug that blocks that mutation, that is what is going to guide and drive our treatment. Sometimes that can take a bit of time, right? And if we have a patient and they just find out they have metastatic disease, will they want treatment yesterday. And I understand that. … But frequently there is a very important period of waiting and allowing us to learn that enemy better by reviewing genomic testing, looking at that next-generation sequencing, looking at any positive biomarkers in breast cancer. They may have started out ER/PR positive. Are they still ER/PR positive?” TS 23:46 “I think when we're talking about goals of care, first of all, we need to make sure that the patient understands, when we're talking about metastatic disease today…, this is not a disease that we can cure, but hopefully it's a disease that we can manage for years to come. With that in mind, what's important to that patient? What is important to that patient in terms of life goals? What's important to that patient in terms of toxicities that they will allow and toxicities that they won't allow? TS 29:22 “If don't have a lot of medical knowledge, taking a pill seems less important than getting an IV. It seems like a bigger deal if I would miss getting my IV therapy. ‘Oh, whoops, I forgot to take a pill. Maybe it's not such a big, important piece of my treatment.' So education—when we set that patient down, helping them understand how this drug works, mechanism of action in a simple term, why it's important to take it as scheduled, why it's important to take it with food or without food, why it's important to take it consistently.” TS 34:41

Plant-Based Diet Improves Outcomes in Metastatic Breast Cancer by Citeline

In this raw, refreshing, and beautifully honest episode, Wren, the founder of the Living Our Breast Lives Podcast is joined by the vibrant Bethany Adair—a woman who's not just living with Metastatic Breast Cancer (MBC), but living the f*ck out of life despite it. From the moment she opens up, Bethany invites us beyond the diagnosis and into her world: her passions, her community, her writing, and her unshakable authenticity.We explore the realities of MBC—from diagnosis and treatment to mental health, anxiety, and the emotional exhaustion that comes with being seen as “the strong one.” Bethany shares how she balances joy and grief, hope and hardship, strength and softness—all while building a life filled with meaning and purpose.She also talks about breaking the mold of toxic positivity in the cancer space, and why vulnerability might just be the bravest act of all. As an author, she opens up about how Metastatic Breast Cancer has shaped her voice and the messages she wants to share with the world.Whether you're living with MBC, love someone who is, or just want to hear a powerful story about resilience, identity, and living out loud—this episode is for you. It's real, it's raw, it's relatable, and most importantly—it's a reminder that life is still worth living, even in the messiest, most uncertain moments.Living Our Breast Lives Information:Email: livingourbreastlivespodcast1@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morrBethany Adair's Information:Email: Bethany@mygurucancer.comWebsite: www.mygurucancer.comBook: My Guru Cancer: You Don't Have to Fight to Find True Freedom from the C Word (found on Amazon + most online retailers)Instagram: @mygurucancerFacebook: @mygurucancer TikTok: @mygurucancerNewsletter: http://eepurl.com/bySU1X

Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00) Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract  Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13) Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract  Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.  Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06) VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.  Selective review of trials of oral SERDs in the adjuvant setting (11:27) A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054 CME information and select publications

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract  Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications